Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | NPY1R | P25929 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | RORA | P35398 | 1/20 | 0.35 |
| ▸ | RORB | Q92753 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5795412 | 0.79 | CYP1A2 (0.54) | PTGER4CYP1A2CYP2C19CYP19A1L3MBTL1 | |
| SCHEMBL21027050 | 0.73 | KDM4E (0.63) | L3MBTL1 | |
| SCHEMBL19179039 | 0.72 | CYP1A2 (0.50) | PTGER4CYP1A2CYP2C19CYP19A1L3MBTL1 | |
| SCHEMBL6573741 | 0.71 | PSEN1 (0.49) | L3MBTL1RORCRORARORBCNR2 | |
| SCHEMBL22441902 | 0.71 | PTGER4 (0.45) | PTGER4CYP1A2CYP2C19CYP19A1L3MBTL1 | |
| SCHEMBL7140681 | 0.71 | NPC1 (0.53) | CYP1A2CYP2C19L3MBTL1RORCRORA | |
| SCHEMBL21027753 | 0.68 | MEN1 (0.57) | L3MBTL1 | |
| SCHEMBL8503624 | 0.68 | KMT2A (0.44) | PTGER4L3MBTL1RORCRORARORB | |
| SCHEMBL13471701 | 0.67 | PTGER4 (0.50) | PTGER4L3MBTL1RORCRORARORB | |
| SCHEMBL21027250 | 0.65 | GLA (0.66) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9289414-B2 | Carbazole formulations for the treatment of psoriasis and angiogenesis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-22 | — | — | US | disclosed |
| EP-1896035-B1 | Carbazole formulations for the treatment of psoriasis and angiogenesis | ARBISER JACK L (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20130338207-A1 | CARBAZOLE FORMULATIONS FOR THE TREATMENT OF PSORIASIS AND ANGIOGENESIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-12-19 | — | — | US | disclosed |
| EP-1896035-A2 | CARBAZOLE FORMULATIONS FOR THE TREATMENT OF PSORIASIS AND ANGIOGENESIS | Arbiser, Jack (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006002082-A2 | CARBAZOLE FORMULATIONS FOR THE TREATMENT OF PSORIASIS AND ANGIOGENESIS | ARBISER JACK (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20060003966-A1 | Carbazole formulations for the treatment of psoriasis and angiogenesis | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003966-A1 | Carbazole formulations for the treatment of psoriasis and angiogenesis | FLT4, ERBB3, EGFR | PTGER4 1001/4885CYP1A2 1531/4885CYP2C19 1219/4885 |
| US-20130338207-A1 | CARBAZOLE FORMULATIONS FOR THE TREATMENT OF PSORIASIS AND ANGIOGENESIS | FLT4, ERBB3, EGFR | PTGER4 1001/4885CYP1A2 1531/4885CYP2C19 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.